• Amid increasing concerns about personnel security from criminal elements, autonomous security robot maker Knightscope is advancing efforts to help make America the safest country in the world
• Knightscope’s AI-enhanced robot sentries have been deployed to Fortune 1000 companies, hospitals, police departments, municipalities, utilities and casinos
• The company’s models include stationary robots as well as mobile products that patrol indoor and outdoor locations
• The robots use artificial intelligence and feature 360-degree eye-level HD streaming video, autonomous recharging, face and license plate recognition, and infrared thermal detection to deter crime and transmit safety or investigational information
• The sentries have the added benefit of being unaffected by the infectious contagion hampering the performance of many employees while the COVID pandemic remains in effect

Autonomous robot manufacturer Knightscope aims to make the United States the safest country on earth with the help of its artificial intelligence-enhanced machines. Knightscope’s current product lineup hinges on the performance of its K1 stationary robot, its indoor-roving K3 model and its outdoor perimeter-patrolling K5 sentry. The company’s robotic platform is designed to potentially reduce the costs of providing security while avoiding not only physical obstacles in their path, but some of the emotional limitations of human patrols as well, such as fatigue, boredom, texting and even fear or anger. Far from the armed profile of movie industry Robocops, or even the more real-world use of National Guard forces supporting U.S. Capitol security forces in the wake of this month’s deadly incursion by domestic terrorists against Congress and ahead of the inauguration of President-elect Joe Biden (https://ibn.fm/4vFhz), Knightscope’s robotic patrols surveil property grounds without weapons but provide a deterrent to crime through their capacity to detect, record and communicate details of incidents for further investigation.  They also provide officers and guards unprecedented situational awareness. Knightscope’s machines are in service across the country, having been deployed at numerous Fortune 1000 companies, hospitals, police departments and the Veterans Administration. Features such as 360-degree eye-level HD streaming video, speakers for live or recorded communication, face and license plate recognition, and broadcast signal reception make the robots capable of responding to a variety of scenarios during their patrols. Their thermal anomaly detection technology has also helped alert authorities to the budding possibility of a fire emergency before the situation got out of hand (https://ibn.fm/WoIYY). During the ongoing pandemic crisis, the sentries have the added benefit of being unaffected by a viral illness. While the autonomous robots arose out of the same philosophy propelling the transportation industry toward self-driving cars and shuttles, Knightscope CEO William Santana Li said during a recent fireside chat hosted by IPO Edge that he set aside his automotive industry background for the more market-responsive parallel venture in the realm of security to commercialize AI-driven technology (https://ibn.fm/h3iCZ). “Depending on who you believe, over $80 billion has been invested in self-driving autonomous (automobile) technology. There are 200-plus companies working on it. How many people in the audience did a transport or moved something or moved themselves this week in an autonomous vehicle? Nobody, right? So $80 billion went into the sector, nobody shipped anything that’s commercially viable,” Li said. “I believe Knightscope is the only company in the world operating 24/7/365 across an entire nation, fully autonomous, no human intervention, with real-world clients and real-world environments.” Li’s vision of platform development equates the self-driving car build-up to trying to travel to Pluto before learning to travel to the moon. Knightscope’s security robots are responsive to an actual societal need and represent a logical, incremental approach by the company. The company’s funding profile is backed by more than 18,000 investors (and growing) through its Reg A+ offering, with security officers of large corporations, shopping mall directors, municipal police officers and federal agents on board. Market analysts at Mordor Intelligence foresee the global market for autonomous security robots reaching $3.59 billion by 2025, and its most recent report gives a shout-out to Knightscope’s K5 model by stating it signals significant progress in the technology, adding, “Earlier, these robots had insufficient capabilities; however, with advances in sensor technology and automation capabilities, these robots have been developed to be useful in working applications” (https://ibn.fm/7KdR6). For more information, visit the company’s website at www.Knightscope.com. Visit www.Knightscope.com/invest for a summary of Knightscope as an investment, with a blue Instant Messaging button for direct contact with their CEO. DISCLAIMER: You should read the Offering Circular and risks related to this offering before investing. This Reg A+ offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/Knight

• December 1, 2020 marked one-year anniversary since recreational marijuana use was approved for sale in Michigan
• Retailers have sold approximately $450 million worth of recreational marijuana products over the last year, with sales averaging $13 million per week in recent months
• Gage Cannabis has leveraged upon rising growth rate through rapid store expansion, which will see its store footprint grow by over 10 locations in 2021
• Michigan’s governor recently signed legislation which will allow veterinarians to speak to pet owners about giving cannabis to their animals for therapeutic use

On December 1, 2020, Michigan marked the one-year anniversary following the legalization of recreational marijuana use within the state. Initially approved by voters in November of 2018, retail sales would have to wait a further 13 months until state officials had built a regulatory system to manage the fledgling industry. Gage Cannabis, a leading vertically integrated cannabis operator currently focused exclusively on the Michigan market, has been one of the prime beneficiaries from the legislative measures.

Since retail sales began on December 1, 2019, weekly sales numbers for adult use products have enjoyed a steady climb. Over the past twelve months, retailers have sold approximately $450 million-worth of recreational marijuana products in the state of Michigan – with average sales rising to over $13 million a week in recent months (https://ibn.fm/Hurkh).

“I would say we’re not even close to market saturation yet,” said Michigan Cannabis Industry Association executive director Robin Schneider in relation to explosive growth in sales.

Gage Cannabis has been able to partake in the region’s rapid growth trajectory as a by-product of the company’s aggressive expansion plan – one that has seen them open 6 medical or adult-use locations across the state, with a further 10+ locations slated to open in 2021. The company has also announced its intentions to raise up to $50 million in gross proceeds through a regulation A+ offering (https://ibn.fm/uv2uj), with a portion of the proceeds set to be re-invested towards financing the company’s various growth initiatives.

The new year has brought about the prospect of a further distinctive sub-sector opening within the wider Michigan cannabis market. In early January, Michigan’s governor signed legislation allowing veterinarians to speak to pet owners regarding the possibility of giving cannabis to their animals for therapeutic use (https://ibn.fm/bLRXH). While the US Food and Drug Administration – which also oversees pet foods and drugs – has yet to authorize CBD for pets, sales of CBD products for pets has seen remarkable growth, with total annual sales in the United States rising from a mere $58 thousand in 2016 to over $7.3 million as of 2019, according to market analytics giant Nielsen Global Connect (https://ibn.fm/cmZ56).

Boasting a strong foothold within the domestic Michigan cannabis market and with the potential of further expansion within the state set to vastly expand the company’s total addressable market, Gage Cannabis now finds itself in an advantageous position to fuel its ongoing growth trajectory. With recent weekly growth trends implying potential recreational marijuana sales growth of over 50 percent over the next year, the Michigan cannabis market may just be the place to be.

For more information, visit the company’s website at www.GageUSA.com.

NOTE TO INVESTORS: The latest news and updates relating to Gage Cannabis are available in the company’s newsroom at https://ibn.fm/GAGE

• The number of bladder cancer cases in 2020 is estimated at 81,400, nearly 4.5% of all newly diagnosed cancer cases, and the current bladder cancer research market is projected to grow at a CAGR of 4.03% through 2026
• White light, the most widely accepted current standard of care for bladder cancer removal, may not be the best option in helping to prevent recurrence, leaving hundreds of thousands of patients afraid of relapse
• Blue light has been introduced and proven to detect 25% more tumors, but because of limitations, has not been widely accepted
• Imagin Medical’s i/Blue Imaging System(TM) can be used alongside the current surgical endoscopic tools for a side-by-side comparison of both white and blue-light imaging in real time

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, is focused on establishing new standards of care in the visualization of cancer during minimally invasive procedures. With an initial focus on bladder cancer, the company aims to address the limitations surgeons face during cystoscopies. The current standard of visualizing bladder cancer during surgery is white light illumination, a procedure that has been used for more than three decades and commands 90 percent of the market.

White-light illumination is effective when it comes to visualizing cancerous tumors protruding above the bladder wall, but flat tumors can look the same as normal tissue and are almost impossible to visualize with white light.

These limitations are successfully overcome with the use of blue light. The problem, however, is that blue light cannot be used during removal of the cancer. Surgeons are therefore required to switch back and forth between white light and blue light during surgeries, losing the real-time observation comparison advantage.

Imagin Medical’s proprietary i/Blue Imaging System(TM) addresses the limitations surgeons face in this regard by simultaneously displaying both white-light and blue-light images side by side, in real time.

Using an FDA-approved imaging agent, the i/Blue System is unlike other systems available on the market today in that it can attach to almost any endoscope model that is currently on the market. Due to this compatibility, any hospital adopting the i/Blue Imaging System will be able to do so in a cost-effective manner without needing to replace their current surgical instruments.

The technology has the potential to revolutionize the current standard of care for bladder cancer patients and help position Imagin Medical as a leading provider of effective solutions in the vast market of bladder cancer research and therapeutics. Bladder cancer is the sixth most prevalent form of cancer and the most expensive one to treat in the United States. The number of new bladder cancer cases in the next year is estimated to reach 81,400, or 4.5% of all newly diagnosed cancer cases, while the estimated number of deaths from bladder cancer in likely to reach 17,980, or 3% of all cancer-related deaths (https://ibn.fm/bjiHj).

According to Verified Market Research, the global bladder cancer research market reached $3.43 billion in 2018. Through 2026, the market is expected to grow at a CAGR of 4.03%, resulting in a projected $4.71 billion in total market growth (https://ibn.fm/HkgN1).

Of all the forms of cancer, bladder cancer has one of the highest recurrence rates among all cancer forms. This leaves an estimated 600,000 people living in fear that their cancer will return, according to Imagin Medical. The company is committed to addressing these fears and making the i/Blue System more broadly accessible for the removal of cancer, potentially lowering recurrence rates.

Imagin Medical announced in late November that it had closed the first $750,000 tranche of a proposed offering of up to $3 million of convertible notes. All securities that have been issued in connection with this offering will be subject to the statutory hold period of four months plus a day from the date of issuance (https://ibn.fm/yzjHS).

For more information, visit the company’s website at www.ImaginMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

• PacRoots Cannabis updated investors following first successful hemp harvest derived from joint venture with Rock Creek Farms
• Initial harvest yielded 105,000 lbs of biomass of exceptional quality; yield was sold in its entirety to Speakeasy Cannabis Club
• Harvest was particularly remarkable given that it was produced despite region’s poor prevailing weather conditions
• Global CBD oil, consumer health market poised to grow to value of $123.2 billion by 2027

PacRoots Cannabis (CSE: PACR) (OTCQB: PACRF), a Canada-based cannabis company dedicated towards producing premium-quality strains and products by leveraging a genetics-focused approach, has recently updated its investors and stakeholders following the company’s first successful hemp harvest on its 100-acre site situated in British Columbia’s South Okanagan Valley (https://ibn.fm/0lGHr). Following the award for an industrial hemp license by Health Canada on May 22, 2020, which permitted Pac Roots Cannabis Corp. to cultivate, sell, possess and process industrial hemp, the Company entered into a binding letter of intent with Rock Creek Farms to form a joint venture with the intent to plant hemp CBD seedlings on 100-acres of prime arable land in British Columbia (https://ibn.fm/7dMzT). Planting commenced in mid-June 2020, with approximately 130,000 premium hemp CBD plants placed systematically throughout the two 50-acre parcels comprising the site. PacRoots revealed that its initial harvest had been a remarkable success, yielding a quality which was far higher than expected; the Company also announced that the entire biomass yield of over 105 thousand pounds is being processed and sold to Speakeasy Cannabis Club (CSE: EASY).  Furthermore, PacRoots elaborated on its low-cost production capabilities, which the Company believes provides it with a decisive and sustainable competitive advantage while continuing to maintain healthy profit margins. “We are very proud of our team and partners at Rock Creek Farms who have been committed to the vision and dedicated to achieving success […] PacRoots and our partners are thrilled to build on this success as we launch into 2021 with various exciting projects,” said PacRoots Cannabis President and CEO Patrick Elliott in reference to the harvest. The Company also highlighted the remarkable nature of the harvest, given that it had come amid less-than-ideal meteorological conditions. British Columbia’s spring season in 2020 was decidedly atypical, with a wet spring and a cold harvest, while the fall ended earlier than usual with freezing temperatures and snow.  PacRoots and Rock Creek Farms were able to limit the frost exposure and damage to their hemp crop through a series of measures, including staggered planting and harvest, system controls, several varieties of genetics and a strong personnel crew, all of which in combination enabled the joint venture to recover far more biomass than would have been expected. “2020 has thrown many things at us, the latest was snow and freezing weather that broke all records in the area dating back to 1886 when they began keeping records in Rock Creek,” remarked the joint venture’s operation advisor Marc Green. “We feel fortunate to have recovered most of the biomass from the 100-acres while most of our peer group failed to recover any significant yield.” Going forward into 2021, the PacRoots Cannabis – Rock Creek Farms joint venture anticipates a strong planting season, seeking to build upon the lessons learned over the prior season. With the global CBD oil and CBD consumer health market set to grow to a market value of $123.2 billion by 2027 (https://ibn.fm/ubKCP). PacRoots Cannabis Corp. seems well poised to benefit from the explosive growth in demand for their product. For more information, visit the company’s website at www.PacRoots.ca. NOTE TO INVESTORS: The latest news and updates relating to PACR are available in the company’s newsroom at http://ibn.fm/PACR

• Ease of use, compatibility with third-party EEG amplifiers has created diverse target markets for BRSF’s NeuroCap
• Recent forecasts show telemedicine industry expected to experience CAGR of 15.1% through 2027
• BRSF has potential to disrupt sleep industry, which is forecast to reach $585 billion by 2025

Brain Scientific (OTCQB: BRSF) is offering solutions to the EEG industry’s limitations. The current method of administering an EEG is slow and expensive, plus requires specialized EEG technologists and bulky equipment. This essential procedure is not easily accessible to all, particularly those in rural communities, because of the expense and a neurologist shortage.

The NeuroCap(TM) is Brain Scientific’s patented, disposable EEG headset. FDA cleared, the revolutionary device can be set up by any clinical personnel within five minutes. The headset is third-party compatible and has no bulky equipment. The NeuroCap makes EEGs accessible to anyone who needs one.

The ease of use and compatibility with third-party EEG amplifiers has created a diverse target market for NeuroCap. Typically EEGs are administered primarily at hospitals or neurology practices, but the NeuroCap makes EEGs available to other markets not previously seen as viable options.  Two growing industries that Brain Scientific plans to target as potential markets are telemedicine and sleep studies.

Last year — 2020 — saw a significant increase in telemedicine. The CDC reported that the first quarter of 2020 saw an increase of 50% from the previous year while week 13 experienced a 154% increase (https://ibn.fm/hA0Rc).

Dr. John Hixson, an associate professor of neurology at the University of California San Francisco and the San Francisco VA, described the NeuroCap as an attractive device in situations where there is no standard of care currently. “In community hospitals, they typically don’t have EEG resources,” noted Hixon, “Yet the question of whether a person is having a subclinical seizure or not comes up quite frequently” (https://ibn.fm/BwArg).

Nurses at these facilities would be able to apply the headset, collect the EEG signals quickly and then access a neurologist remotely, Hixon explained.

Changes in the CPT Code, or numbers used to identify medical services and procedures furnished by qualified healthcare professionals, show a significant change in outpatient codes, the first large overhaul in more than 25 years (https://ibn.fm/YMfPW). This change reflects the changes within the industry as the demand for telehealth continues to increase.

In 2019, the telemedicine market size was estimated at $41.4 billion globally, and recent forecasts show the industry is expected to experience a compounded annual growth of 15.1% through 2027. Part of this increase is credited to the need for improved care while also reducing the burden on medical professionals (https://ibn.fm/q2Jwp).

Telemedicine is not the only sector in need of portable, low-cost, reliable equipment. The sleep industry is seeing an uptick in clients as 50 to 70 million people in the United States suffer from one or several sleep disorders. With more than 4,700 sleep centers and labs across the country, these potential patients can access the care they need (https://ibn.fm/3G0a0). Many of them will need an EEG as abnormalities in sleep may be a sign of neurologic disorders (https://ibn.fm/56K5T).

There is a move within the sleep clinics to provide at-home sleep studies due to the convenience and lower cost. However, at-home studies only monitor breathing. The addition of the NeuroCap to a sleep clinic’s toolbox will provide higher convenience. With the sleep industry worldwide expected to reach $585 billion by 2025 (https://ibn.fm/JEL1m), this is a lucrative market BRSF has the potential to disrupt.

Brain Scientific is creating innovative ways to make a much-needed medical procedure more accessible to all.

For more information, visit the company’s website at www.BrainScientific.com.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• Following the success of the Venue Bubble and Travel Bubble projects, Loop has partnered with Draganfly Inc. to launch the first Film Bubble for a major motion picture in January 2021
• The film and television industry has seen a significant drop in revenue, and the Film Bubble is positioned to make sets safer with the technology provided by Draganfly
• Effective December 11, 2020, Mark Lotz took over the position of Chief Financial Officer after the resignation of Abbey Abdiye

Loop Insights (TSX.V: MTRX) (OTCQB: RACMF), an innovative Internet of Things (“IoT”) technology company that delivers contactless solutions, including venue management, personalized engagement, and AI-driven insights, is partnering with Draganfly Inc. (CSE: DFLY) (OTCQB: DFLYF) (FSE: 3U8)) to launch the first “Film Bubble,” a solution designed to help keep movie sets safer and operational during the coronavirus pandemic (https://ibn.fm/tJAKt). The Film Bubble provides another major opportunity for Loop as a spin-off of the recently successful NCAA Venue Bubble and Travel Bubble projects. According to Loop CEO Rob Anson, the Film Bubble will provide a great showcase for the company’s film industry solution as well as additional opportunities for travel, venue, and other healthcare applications Loop Insights has been working on. The Film Bubble will be launched for a major motion picture scheduled to commence filming in January 2021. At this time, the names of the motion picture and the actors are being kept confidential until filming begins. Under the partnership agreement, Loop Insights and Draganfly will combine technologies into Loop’s Venue Bubble solution with the ultimate goal of making the film and television industry safer to resume production, resulting in higher revenue and employment opportunities. “Film industry investors, insurance companies, unions, and guilds are all seeking this type of solution to keep workers safe and protect their investments,” Draganfly CEO Cameron Chell said. Draganfly provides Safe Set Solutions for the global film and television production industry using ground-based technology for symptom pre-screening, elevated body temperature measurement, and social distancing display. The Film Bubble solution comes at the right time for an industry that has reported billions in losses as a result of the coronavirus pandemic closing down movie theaters and production. In 2019, the North American box office amounted to $11.32 billion in total earnings and employed over 456 thousand people with several hundred thousand more employees in Canada and other countries worldwide (https://ibn.fm/hVmFz). This past November, AMC Theatres announced that they had seen a 91% drop in their revenues during the most recent earnings period resulting in a loss of $906 million in this quarter alone. The overall global entertainment industry is also projected to lose $160 billion of growth over the next five years (https://ibn.fm/Kr0Wj). “The addition of Draganfly’s Safe Set Solutions to our Venue Bubble Platform creates an instant and powerful Film Bubble solution for an industry that has suffered catastrophic losses in 2020 and can’t afford to stay shut down for a minute longer,” Anson said. “We are extremely proud to have jointly delivered a solution to the film industry that will allow them to safely get their crews, actors, and supporting infrastructure back to work and generating prosperity, the ripple effects of which reverberate around the world.” On the same day the Film Bubble partnership was made public, Loop Insights announced the appointment of a new Chief Financial Officer. The previous CFO, Abbey Abdiye, resigned from the company to pursue other career opportunities. He is replaced by Mark Lotz, who took over the position effective December 11, 2020 (https://ibn.fm/Vicrd). Lotz is a Chartered Professional Accountant with 26 years of post-qualification experience. His experience spans across a broad cross-section of industries that include SaaS, mining, manufacturing, financial service, and technology. Lotz has a Bachelor’s degree in Business Administration with a dual Economics major. Backed by Amazon’s Partner Network, Loop has developed a line of powerful technologies that are simple to use but designed to transform industries. Fobi, an IoT device that is designed to seamlessly integrate with any existing point of sale infrastructure, collects 100% of the transactional data and sends it to the cloud. SmarTap is Loop’s Near Field Communication (“NFC”) device that enables consumers to check-in using a “tap” and their smartphone’s NFC compatibility. SmarTap offers a contactless consumer experience and connects with the cloud via LTE or WiFi to securely transmit data. Loop Cloud is the middle ground where Fobi and SmarTap’s information meets, being stored digitally and creating a database for the company and their clients. When paired with either Loop solution, the Loop Cloud creates a way for the business to transform their edge-based legacy systems into a unified database. For more information, visit the company’s website at www.LoopInsights.ai. NOTE TO INVESTORS: The latest news and updates relating to RACMF are available in the company’s newsroom at https://ibn.fm/RACMF

• MAZAKALI’s management team has vast experience in the cannabis industry, helping uniquely position the company to dominate one of the fastest-growing industries in the world
• The MAZAKALI management team has extensive experience at Fortune 500 companies, including UBS, JP Morgan, Merrill Lynch, Apple, AliBaba and AT Kearney
• The cannabis market is expected to reach $73.6 billion by 2027, growing at a CAGR of 27%
• The company places authority and knowledge on the same pedestal, providing GreenPapers(R) as a valuable educational tool for the public on all topics and trends related to the high-growth cannabis industry; over 70 GreenPapers(R) have been published since 2016, attracting over 70,000 subscribers to date
• The MAZAKALI investment team is comprised of licensed investment bankers and Registered Investment Advisors; securities are offered via a registered broker/dealer
• MAZAKALI’s online marketplace serves cannabis capital formation with scalability, sustainability and sensibility
• MAZAKALI aims to create a healthier and sustainable world through the purposeful placement of capital

A cannabis-focused fintech marketplace based in San Francisco, MAZAKALI offers investment opportunities in the high growth cannabis industry. Supported by a broker/dealer and acting as a Registered Investment Adviser, the company has been supporting cannabis businesses in raising capital since 2016. MAZAKALI was founded to counteract the negative consequences of business practices by making investments in sustainable cannabis. By shepherding capital in a responsible and ethical manner, MAZAKALI and its clients envision a world where capital investment will play a significant role Beyond Impact. The company’s financial services leverage deep relationships, rigorous analytics and reliable research focused on uncovering investment opportunities in the high growth cannabis sector. The company features a deep bench of educated, experienced and licensed professionals to support clients with their capital and investment needs. Investor Services

• Online Investment Marketplace:Investors gain access to a pipeline of vetted investment opportunities; diversified across sectors and geography. In addition to direct investments, MAZAKALI offers managed funds and custom portfolios.
• Custom Portfolios:Investors seeking to place capital in excess of $1MM can take advantage of separately managed accounts designed and managed by licensed investment advisors. Custom portfolios offer several advantages over collective funds, including personalization, reduced expenses and tax benefits.
• Institutional Investor Services:MAZAKALI introduced the first Outsourced Cannabis Investment Officer (“OCIO”) service in 2019, providing its portfolio management expertise to those institutions with capital and interest seeking knowledge and access.

Issuer Services Every successful capital raise begins with proper preparation. Since its inception, MAZAKALI has specialized in supporting cannabis-related businesses by helping them prepare to raise capital. Cannabis firms that collaborate with MAZAKALI gain access to insight acquired through the hands-on experience of MAZAKALI’s management team. By providing comprehensive services throughout the entire fundraising process, MAZAKALI helps businesses save time and show well to potential investors at every stage. The company’s services include:

• Preparation stage:Initial consultation, business review, structural analysis, strategic planning, expansion agenda
• Structure offering stage:Capital advisory, capital cadence, deal structure, financial instrument selection, initial raise terms
• Modeling stage:Pro Forma financials, income statement, balance sheet, cash flow statement, assumption review, business valuation
• Pitch preparation stage:Pitch deck, investment deck, pitch practice, Q&A practice, pitch video
• Offer launch stage:Digital platform listing, pitch video, term sheet, Pro Forma model, financials, cap table, subscription docs, automated workflow, offer marketing

Education – GreenPapers(R) The company believes in ‘Authority Through Knowledge’. To help educate the public about the cannabis markets, MAZAKALI uses GreenPapers(R) to share deep trends and insights that matter to investors and operators alike. GreenPapers(R) archives span from 2016 to the present, with the most recent insight report focusing on major cannabis trends in 2021. Titled Cannabis 2021: Five Things to Watch, the report underlines that 2021 is poised to be a pivotal year for the cannabis sector amid growing political support, legalization in 70 percent of U.S. states, increased public focus and local governmental interest in gaining tax revenue from the market (https://ibn.fm/sAT1z). All of these factors and more are likely to make cannabis the best performing asset class of the decade, the report forecasts. The report also lists the five major trends expected in 2021:

• Rise of the cannabis beverage
• Biosynthesis
• Accelerated state and local market adoption
• Expanded capital participation
• Global growth

Technology MAZAKALI’s online marketplace was designed to provide compliance, convenience and confidence to the cannabis private equity investment process. The company’s investment services include education, research and execution on an intuitive digital interface. Investors can gain exposure to direct placements, managed accounts and third-party funds in a compliant and convenient marketplace. Market Outlook The global growth forecast by MAZAKALI is backed by other analysts and experts in the niche. According to Grand View Research, the global cannabis market is expected to grow exponentially amid increased acceptance of the plant worldwide. The industry is anticipated to reach $73.6 billion by 2027, expanding at a CAGR of 18.1%. In 2019, the largest revenue shares for cannabis belonged to North America, resulting in 88.4% of the worldwide market (https://ibn.fm/vmq3Z). According to a BCC Research report, the plant-based and botanical-derived drug market is also expected to grow globally and reach an estimated $39.6 billion valuation by 2022, marking a CAGR of 6.1% from the 2017 market value of $29.4 billion (https://ibn.fm/3f717). Management Team Sumit Mehta is the Founder and CEO of MAZAKALI. A cannabis strategist, Mr. Mehta is an internationally recognized speaker and the author of the MAZAKALI GreenPaper(R). In addition to his role leading MAZAKALI, Mr. Mehta serves on several cannabis company boards and is the Chair of the Banking and Financial Services committee for the National Cannabis Industry Association. Mr. Mehta is the former Director of Finance for the Arcview Group and, prior to entering the cannabis industry full-time in 2016, spent 20 years on Wall Street at firms including JP Morgan, UBS and Merrill Lynch. Mr. Mehta has earned an MBA from the Ross School of Business at the University of Michigan and a BA with Honors in Economics with minors in Math and Physics from the University of Texas at Austin. Mr. Mehta holds FINRA 7, 63, 65 and 79 licenses, as well as a Certificate in Financial Technology from Harvard University. Craig Piatti is the company’s Chief Operating Officer. He is responsible for developing and driving the firm’s infrastructure, technology and organizational processes. Prior to joining MAZAKALI, Mr. Piatti worked at Alibaba’s cloud computing division on strategic business development. He has also worked with global firms including SAP, Bosch and China Telecom. He holds an MBA from the University of Notre Dame – Mendoza College of Business and a BS from Indiana University – Kelly School of Business. He also holds a Diplom-Betriebswirt (“BWL”) from Reutlingen University in Germany and a FINRA 65 license. Mary Beth Barron is MAZAKALI’s Chief Marketing Officer. Ms. Barron leads the company’s marketing strategy, brand management, communications, advertising, public relations and digital marketing. Bringing more than 20 years of marketing and business leadership experience, her career started at Apple Far East (Hong Kong). She served as a top marketing leader for several global professional services – giving her marketing responsibilities in more than 30 countries. Ms. Barron holds an MBA from the Kellogg School of Management at Northwestern University and a BA from The Colorado College. Bob Peatman is the Director of Investments for MAZAKALI. Mr. Peatman is responsible for assisting wealth managers and investors with cannabis-related investment opportunities. Mr. Peatman has worked with retail and institutional investors throughout his financial career, with a focus on digitizing and expanding national sales distribution networks. He holds an MBA from Babson College and a BA from St. Lawrence University. Justin Schleifer is MAZAKALI’s Director of Compliance. Mr. Schleifer is responsible for developing the firm’s controls and overseeing its advisory business. He is also the CEO and Co-Founder of Aspect Advisors, a San Francisco-based compliance consulting firm for asset managers, broker-dealers and fintech businesses. Schleifer has extensive experience interfacing with the SEC, FINRA and the NFA. He earned his BS in Hotel Administration, concentrating in Business Law, from Cornell University. He also holds FINRA Series 7, 24, 27, 55, 66, 79 and 87 licenses. Mathew Auric serves as Legal Counsel for MAZAKALI. In his role, Mr. Auric is responsible for general legal support, including contract drafting and negotiation, internal business structuring, strategic planning and liability management. Mr. Auric is a corporate attorney with cannabusiness firm Hoban Law Group, with a deep understanding of the regulatory, practical and historical issues involving cannabis. He received his JD from Ventura College of Law and a bachelor’s degree from the University of California, Santa Cruz. For more information, visit the company’s website at www.MAZAKALI.com. NOTE TO INVESTORS: The latest news and updates relating to MAZAKALI are available in the company’s newsroom at https://ibn.fm/MAZAKALI

• Josemaria Resources developing its wholly owned flagship Josemaria Copper-Gold Project
• VanEck report details investment value of ‘junior’ mining companies
• Global smart mining market estimated to reach $6.8 billion last year, forecast to reach $20.31 billion by 2025

For investors looking for high-growth potential, junior mining companies may fit the bill, according to a recent report released by VanEck, an investment management company (https://ibn.fm/Cvv8W). That’s good news for Josemaria Resources (TSX: JOSE) (OTCQB: JOSMF), a natural resources company that is offering an advanced-stage copper-gold deposit project located in Argentina, a rare find in a junior mining company.

The VanEck report, titled “The Investment Case for Junior Gold Miners,” notes that “a dynamic and important subset of the global gold-mining industry is a group of companies known as ‘juniors.’ These are small- to medium-size market capitalization companies that are generally actively engaged in the development of new sources of gold either through greenfield exploration or the use of new geologic models to prospect for gold in overlooked or abandoned properties. For investors, juniors may offer characteristics similar to an investment in venture capital—early stage, high risk, but with a potential for high growth.”

Josemaria is looking for that type of high-growth return as it eyes key growth in a global smart mining market that was estimated to reach $6.8 billion last year and forecast to reach $20.31 billion by 2025 (https://ibn.fm/6Cc28). The company is focusing on the development of its wholly owned flagship Josemaria Copper-Gold Project located in the San Juan Province of Argentina. San Juan is a well-known mining hub supporting a wide variety of mining companies, where the Lundin Group, the parent company of JOSE, has been active for almost 30 years.

JOSE recently released the results of a feasibility study for its Josemaria Copper-Gold Project. The study reports a robust, rapid pay-back, low-risk project, with an open-pit operation feeding a conventional process plant at an average of 152,000 tonnes per day. The study also projected a mine life stretching more than 19 years and yielding average annual metal production of 136,000 tonnes of copper, 231,000 ounces of gold and 1,164,000 ounces of silver.

“We are extremely pleased with the results of the Feasibility Study at Josemaria, which indicates that this is one of the very few readily developable copper-gold projects in the world today,” said Josemaria president and CEO Adam Lundin. “This study has materially de-risked the project and forecasts an attractive economic outcome which is comparable with other large-scale copper/gold projects already being developed or in production today.”

Josemaria Resources is a Canadian natural resources company based in Vancouver, British Columbia. The company’s current focus is on advancing the development of its wholly owned Josemaria copper-gold mining project. Josemaria Resources is part of the Lundin Group of companies, a conglomerate of 13 business entities operating in the mining, oil and gas and renewables sectors around the world.

For more information on Josemaria Resources, visit the company’s website at www.JoseMariaResources.com.

NOTE TO INVESTORS: The latest news and updates relating to JOSMF are available in the company’s newsroom at https://ibn.fm/JOSMF

• Company extends expiration of special dividend for one year
• If declared, special dividend will consist of number, designation determined by company management
• BIGtoken is first consumer-managed data marketplace where people can own, earn from their data

SRAX (NASDAQ: SRAX) will extend the expiration for its previously announced BIGtoken special dividend right for one year. The dividend right was set to expire on or before 5 p.m. on Dec. 31, 2020, and that deadline has been extended to on or before 5 p.m. ET on Dec. 31, 2021 (https://ibn.fm/sCKWJ). The original dividend right was issued on Sept. 17, 2018, when SRAX, then called Social Reality Inc., announced a nontransferable right to receive at no charge a special dividend to holders of the company’s Class A common stock; the right was also extended to certain holders of the company’s common stock equivalents. The extension announcement notes that “if and when declared, the Special Dividend will consist of such number and designation of the SRAX subsidiary BIGtoken Inc.’s securities as determined by the company’s management at their sole discretion. . . . The Special Dividend will be an analog security, i.e., not digital, and not a cryptocurrency, and the Special Dividend is expected to be a fractional non-voting security that, if and when issued, is expected to only participate in a portion of the financial performance of the BIGtoken platform.” Initially launched by SRAX and then spun off as a separate company, BIGtoken, or BIG, is a secure consumer data-management and distribution system —the first consumer-managed data marketplace where people can own and earn from their data (https://ibn.fm/nr4Sm). Through a transparent platform and consumer reward systems, BIG offers consumers choice, transparency, and compensation for their data. Participants earn rewards, and developers are able to build pro-consumer online experiences on top of the BIG platform (https://ibn.fm/gXpcG). At last count, BIGtoken has compensated more than 16 million users for access to their data while creating data sets across 25,000 unique market segments. Brands are offered access to this verified, opted-in data for a fee. “BIGtoken is a secure platform that empowers you to realize and claim the value of your digital self,” the website observes (https://ibn.fm/B0Cj3). “You have a right to privacy, awareness, and choice when it comes to the data you put out into the digital world. With BIG, you can own and earn from that data while staying connected to your community.” SRAX is currently focused on unlocking data and insights through its software-as-a-service (SaaS) platform, Sequire. Launched as a standalone platform in early 2020, Sequire now has more than 1 million investors and traders, with an estimated 91 publicly listed companies as subscribers. The explosion in growth is driven by Sequire’s extensive range of services and as companies have increasingly sought to adopt digital technology and the data generated from such mediums as a way of improving their engagement with customers and stakeholders alike. For more information about SRAX and Sequire, visit the companies’ websites at www.SRAX.com and www.MySequire.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• IND approval from the FDA has given CNS Pharmaceuticals the green light needed to continue with clinical research of Berubicin in patients suffering from GBM and other brain/nervous system cancers
• Company holds the exclusive worldwide license for Berubicin, the first anthracycline to cross the blood-brain barrier in the adult brain
• The GBM therapeutics market is expected to increase to an estimated $3.3 billion in 2024
• CNS Pharmaceuticals’ sublicensee will be conducting the first pediatric study using Berubicin

CNS Pharmaceuticals (NASDAQ: CNSP) is a clinical-stage biotechnology company that is currently specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, including the use of Berubicin for patients with glioblastoma multiforme (“GBM”), an aggressive form of brain cancer that is incurable. CNS is currently working on the development and clinical trials of Berubicin for GBM and the potential of addressing other central nervous system malignancies.

Berubicin appears to be the first anthracycline to cross the blood-brain barrier in the adult brain. Its development started over 15 years ago when Reata Pharmaceuticals, Inc. (NASDAQ: RETA) conducted the first Phase I trial, creating limited clinical data. Phase I trial results indicated that 44 percent of participants reported a significant improvement in the size of the tumor. The evidence concluded that there was a positive enough impact that CNS has continued with the development and the clinical-stage trials for the drug.

CNS holds the exclusive license for Berubicin worldwide. The company goes into the year 2021 determined to move forward with the development and distribution of Berubicin for GBM. The recent approval of the United States Food and Drug Administration (“FDA”) of Berubicin as an investigational new drug (“IND”) has only increased the opportunity for CNS to move forward with the three clinical trials currently in development.

“The company will transform within the next several months as Berubicin becomes the subject of up to three active clinical trials, which include our randomized, controlled Phase II trial in the U.S., and two trials planned by our sublicensee WPD in Poland,” CNS Pharmaceuticals CEO John Climaco said during a recent virtual presentation discussing the FDA IND approval and future company plans (https://ibn.fm/TP3oE).

The company’s sublicensee WPD Pharmaceuticals (CSE: WBIO) (FSE: 8SV1) will be conducting a Phase II trial in adults, as well as the first-ever Phase I trial in children who suffer from GBM and other cancers of the brain and central nervous system. This is the first pediatric trial of its kind.

According to Climaco, CNS aims to address the significant unmet medical need of GBM patients since the current treatment paradigm for the condition yields bleak results, and this aggressive and, as yet, incurable form of brain cancer continues to claim high mortality rates. “We have a tremendous opportunity ahead of us as we continue our mission to improve patient outcomes for GBM and build on the promising results demonstrated by Berubicin in its Phase 1 clinical trial,” he added.

The GBM treatments market is anticipated to increase to an estimated $3.3 billion in 2014, marking a CAGR of 17.4% from 2014, when the market was $659. The growth is expected to be driven by seven major markets – the United States, Spain, the UK, France, Italy, Japan, and Germany, and is the direct result of the growing unmet needs of the current market (https://ibn.fm/ZAYjM).

Berubicin is currently being produced in two labs as a result of a dual-track manufacturing strategy implemented by CNS. To ensure that current conditions do not hinder the progress of Berubicin’s development and availability, CNS has turned to United States-based Pharmaceuticals International Inc. and Italy-based BSP Pharmaceuticals SpA for the production of Berubicin for the clinical trials. Both pharmaceutical companies have diversified the supply chain, and increased the availability of Berubicin, mitigating the risks of COVID-19 in clinical trial strategies.

For more information, visit the company’s website at www.CNSPharma.com

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP